association

Full identifier: http://purl.org/np/RANSXtdEyITf8JT0-bZxtl_1uUg_3AV2s0llvfMf_ixLY#association

Assigned to 1 class:

Minted in Nanopublication

 RANSXtdEyI comment approve/disapprove edit as derived nanopublication create new with same template

This is the identifier for this whole nanopublication. http://purl.org/np/RANSXtdEyI... This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal) "2021-06-29T08:05:23.509+02:00" .
This is the identifier for this whole nanopublication. http://purl.org/np/RANSXtdEyI... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAManV5GZI... RAManV5GZI .
This is the identifier for this whole nanopublication. http://purl.org/np/RANSXtdEyI... This nanopublication links to the provenance template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate was created from the provenance template http://purl.org/np/RANwQa4ICW... RANwQa4ICW .
This is the identifier for this whole nanopublication. http://purl.org/np/RANSXtdEyI... This nanopublication links to the publication info template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate was created from the publication info template http://purl.org/np/RAA2MfqdBC... RAA2MfqdBC .

References

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-29T06:05:23.509Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
ethambutol hci is indicated for the treatment of pulmonary tuberculosis it should not be used as the sole antituberculous drug but should be used in conjunction with at least one other antituberculous drug selection of the companion drug should be based on clinical experience considerations of comparative safety and appropriate in vitro susceptibility studies in patients who have not received previous antituberculous therapy ie initial treatment the most frequently used regimens have been the following ethambutol hci plus isoniazid ethambutol hci plus isoniazid plus streptomycin in patients who have received previous antituberculous therapy mycobacterial resistance to other drugs used in initial therapy is frequent consequently in such retreatment patients ethambutol hci should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies antituberculous drugs used with ethambutol hci have included cycloserine ethionamide pyrazinamide viomycin and other drugs isoniazid aminosalicylic acid and streptomycin have also been used in multiple drug regimens alternating drug regimens have also been utilized
Leoni Bücken
2021-06-29T06:05:23.509Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-29T06:05:23.509Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-29T06:05:23.509Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-29T06:05:23.509Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-29T06:05:23.509Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-29T06:05:23.509Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-29T06:05:23.509Z

Raw

TriG(txt), JSON-LD(txt), N-Quads(txt), XML(txt)